
**FIGURE 13.14**

Inactivation of SN-23862 by reductive metabolism.

**FIGURE 13.15**

Bioactivation of the water-soluble PR-104 prodrug by sequential hydrolytic and reductive processes.

both as monotherapy and combined with radiotherapy and chemotherapy.¹⁴ Upon intravenous administration, PR-104 is converted by systemic phosphatases to the alcohol intermediate PR-104A. PR-104A is intracellularly reduced under hypoxic conditions to the hydroxylamine PR-104H, which specifically cross-links hypoxic tumor cell DNA (Figure 13.15). This prodrug has entered clinical trials for advanced solid tumors.¹⁵